Berberidaceae Extract

Icariside I (Standard) is the analytical standard of Icariside I (HY-N1939). This product is intended for research and analytical applications. Icariside I (GH01) is an orally active metabolite of icalin. Icariside I improves estrogen deficiency-induced osteoporosis by simultaneously regulating osteoblast and osteoclast differentiation. Icariside I promotes ATP (HY-B2176) or Nigericin (HY-127019)-induced mtROS production and NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Icariside I does not alter the activation of NLRC4 and AIM2 inflammasomes. Icariside I inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway. Icariside I is a kynurenine-AhR pathway inhibitor that alleviates cancer by blocking tumor immune escape.

Sagittasine A is an isoprenyl flavonol glycoside that can be isolated from Epimedium sagittatum.

Koreanoside G is a flavonol glycoside that can be isolated from the leaves of Epimedium koreanum.

Neo-sagittasine A (compound 2) is an estrogen biosynthesis promoter that can enhance estrogen biosynthesis in human ovarian granulosa-like KGN cells. Neo-sagittasine A can be isolated from Epimedium brevifolium.

Picropodophyllin-4-O-β-D-glucopyranosyl-(1→6)-β-D-glucopyranoside (compound 17) is a lignan isolated from the roots and rhizomes of Podophyllum sinensis.

Picropodophyllol is a triol.